The price of Praluent (alirocumab) has seen reductions through authorized agreements and increased competition. In 2020, Sanofi and Regeneron announced a significant discount on Praluent for certain U.S. Medicare Part D plans, following market access challenges and a lower-than-expected uptake [1]. This move aimed to make the PCSK9 inhibitor more accessible to a broader patient population on these plans [1].
How is Praluent priced for different patients?
Praluent's pricing can vary based on insurance coverage, formulary placement, and patient assistance programs. Before the 2020 discount, Praluent had a list price of approximately $5,700 per year [2]. Sanofi and Regeneron have implemented patient assistance programs to help eligible individuals with out-of-pocket costs [3]. The availability of these programs and the specific terms negotiated with insurers are key factors in the net price paid by patients.
When does Praluent's patent protection end?
Praluent, an injectable PCSK9 inhibitor, has patent protection that impacts when generic or biosimilar versions can enter the market. While specific patent expiry dates can be complex and subject to litigation, DrugPatentWatch.com tracks patents related to drugs like Praluent, providing insights into exclusivity periods [4]. Generally, patent expiry allows for increased competition, which often leads to price reductions.
How do Praluent and Repatha compare on cost?
Praluent and Amgen's Repatha (evolocumab) are both PCSK9 inhibitors and direct competitors. Historically, both drugs faced pricing challenges and uptake issues. Following Praluent's pricing adjustments, the competitive landscape continued to evolve, influencing the pricing strategies of both medications. The introduction of biosimilar or generic versions, once patent protection wanes, is expected to further impact pricing for both drugs.
What led to Praluent's initial high price?
The initial high price of Praluent was a reflection of the significant research and development costs associated with bringing a novel class of drugs like PCSK9 inhibitors to market [2]. The high list price was also a strategy to recoup investment and establish value in a new therapeutic area for managing cholesterol. However, this pricing model faced scrutiny from payers and healthcare systems, leading to the subsequent negotiations and discounts.
Are there Praluent alternatives available?
Praluent is used to lower LDL cholesterol in individuals with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease on maximally tolerated statin therapy [3]. Alternatives for cholesterol management include statins, ezetimibe, bile acid sequestrants, and other lipid-lowering medications. For patients who cannot tolerate statins or require additional LDL-lowering, PCSK9 inhibitors like Praluent and Repatha represent a distinct treatment option [3].
*
**Sources:
[1] https://www.drugpatentwatch.com/news/praluent-price-reduction
[2] https://www.drugpatentwatch.com/drug/praluent
[3] https://www.drugpatentwatch.com/drug/praluent/indications
[4] https://www.drugpatentwatch.com/